trimodulin (BT588) / Grifols 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
trimodulin (BT588) / Grifols
TRICOVID, NCT05531149 / 2022-000736-37: Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia

Recruiting
3
390
Europe, RoW
Trimodulin, BT588, Placebo (human albumin 1%)
Biotest
Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome, COVID-19, Viral Pneumonia, Bacterial Pneumonia, Fungal Pneumonia
08/25
08/25
ESsCAPE, NCT05722938: Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

Recruiting
3
590
Europe, US, RoW
Trimodulin, BT588, Placebo (human albumin 1%)
Biotest
Community-acquired Pneumonia
02/25
04/25
2020-002345-42: A randomized, placebo controlled, double-blind, multi-center, phase II trial investigating the efficacy and safety of trimodulin (BT588) as add-on therapy to standard of care in adult subjects with severe COVID-19 Ensayo en fase II aleatorizado, controlado con placebo, doble ciego, multicéntrico en el que se investiga la eficacia y la seguridad de la trimodulina (BT588) como complemento al tratamiento de referencia en sujetos adultos con COVID-19 grave

Not yet recruiting
2
114
Europe
trimodulin, BT588, Solution for infusion
Biotest AG, Biotest AG
Severe Corona Virus Disease 2019 (COVID-19) Enfermedad grave por virus Corona 2019 (COVID-19), Severe COVID-19 COVID-19 grave, Diseases [C] - Virus Diseases [C02]
 
 

Download Options